Results 11 to 20 of about 346,440 (204)

Clinical characteristics of patients with Breast and / or Ovarian Cancer with mutations in the BRCA1 and BRCA2 genes in Córdoba, Argentina [PDF]

Rev Fac Cien Med Univ Nac Cordoba, 2022
Resumen Introducción Los síndromes de predisposición hereditaria al cáncer representan un 5-10% de los casos de cáncer, el más estudiado es HBOC producido por mutaciones en los genes BRCA1/2.
Martin CA, Suárez Villasmil L, Sembaj A, Gomez Balangione F, Zunino S, Montes CDC, Borello A, Del Castillo A, Zeballos M, Rossi NT.   +9 more
europepmc   +2 more sources

Patient involvement in research within the Gynecological Cancer InterGroup: A call to action for a systematic approach: Results from a survey. [PDF]

Health Sci Rep, 2023
Abstract Background and Aims Involving patients in research, not only as trial subjects, is not a newly established practice. Over the last two decades, patient roles have gradually expanded to become active research contributors, creating a more patient‐centered research landscape.
Nohová I, Andrews J, Votan B, Miller A, Sehouli J, Berger R.   +5 more
europepmc   +2 more sources

Uso de ileostomía derivativa en cáncer de ovario. Revisión de la literatura

Revista Colombiana de Cirugía
Introducción. La ileostomía derivativa de protección se realiza con el objetivo de proteger la anastomosis intestinal después de una resección colorrectal. Esta resección intestinal es el procedimiento extendido más frecuentemente realizado en pacientes
Franco Rafael Ruiz-Echeverría, Pedro Hernando Calderón-Quiroz, Juliana Rendón-Hernández   +2 more
doaj   +2 more sources

Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial

Cancer, Volume 129, Issue 12, Page 1846-1855, 15 June 2023., 2023
Abstract Background The PRIMA/ENGOT‐OV26/GOG‐3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an individualized starting dose (ISD) regimen of niraparib for first‐line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.
Mansoor R. Mirza, Antonio González‐Martín, Whitney S. Graybill, David M. O’Malley, Lydia Gaba, Oi Wah Stephanie Yap, Eva M. Guerra, Peter G. Rose, Jean‐François Baurain, Sharad A. Ghamande, Hannelore Denys, Emily Prendergast, Carmela Pisano, Philippe Follana, Klaus Baumann, Paula M. Calvert, Jacob Korach, Yong Li, Izabela A. Malinowska, Divya Gupta, Bradley J. Monk   +20 more
wiley   +1 more source

Top advances of the year: Cervical cancer

Cancer, Volume 129, Issue 5, Page 657-663, 1 March 2023., 2023
Abstract Cervical cancer continues to affect women in the United States and throughout the world despite an effective vaccine against human papillomavirus and cancer screening programs. For the women who develop cervical cancer, surgery, radiation, and chemotherapy have been the mainstays of treatment for years.
Sarah E. Podwika, Linda R. Duska
wiley   +1 more source

Sinonasal inverted papilloma – malignant transformation and non‐sinonasal malignancies

The Laryngoscope, Volume 133, Issue 3, Page 506-511, March 2023., 2023
Objectives To assess malignant transformation rate, non‐sinonasal malignancies, and factors contributing to recurrence in patients treated for sinonasal inverted papilloma (SNIP). Study Design Retrospective study. Methods We retrospectively reviewed medical records of all patients treated for SNIP (n = 296) between the years 1984–2014 at Helsinki ...
Sanna Viitasalo, Taru Ilmarinen, Leena‐Maija Aaltonen, Jaana Hagström, Maija Hytönen, Sari Hammarén‐Malmi, Petra Pietarinen, Pia Järvenpää, Teemu Kinnari, Ahmed Geneid, Markus Lilja   +10 more
wiley   +1 more source

Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort

Ultrasound in Obstetrics &Gynecology, Volume 61, Issue 2, Page 231-242, February 2023., 2023
ABSTRACT Objective Previous work has suggested that the ultrasound‐based benign simple descriptors (BDs) can reliably exclude malignancy in a large proportion of women presenting with an adnexal mass. This study aimed to validate a modified version of the BDs and to validate a two‐step strategy to estimate the risk of malignancy, in which the modified ...
C. Landolfo, T. Bourne, W. Froyman, B. Van Calster, J. Ceusters, A. C. Testa, L. Wynants, P. Sladkevicius, C. Van Holsbeke, E. Domali, R. Fruscio, E. Epstein, D. Franchi, M. J. Kudla, V. Chiappa, J. L. Alcazar, F. P. G. Leone, F. Buonomo, M. E. Coccia, S. Guerriero, N. Deo, L. Jokubkiene, L. Savelli, D. Fischerova, A. Czekierdowski, J. Kaijser, A. Coosemans, G. Scambia, I. Vergote, D. Timmerman, L. Valentin   +30 more
wiley   +1 more source

ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors

Ultrasound in Obstetrics &Gynecology, Volume 58, Issue 1, Page 148-168, July 2021., 2021
ABSTRACT The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence‐based statements on the preoperative ...
D. Timmerman, F. Planchamp, T. Bourne, C. Landolfo, A. du Bois, L. Chiva, D. Cibula, N. Concin, D. Fischerova, W. Froyman, G. Gallardo, B. Lemley, A. Loft, L. Mereu, P. Morice, D. Querleu, A. C. Testa, I. Vergote, V. Vandecaveye, G. Scambia, C. Fotopoulou   +20 more
wiley   +1 more source

Perspectives, fears and expectations of patients with gynaecological cancers during the COVID‐19 pandemic: A Pan‐European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)

Cancer Medicine, Volume 10, Issue 1, Page 208-219, January 2021., 2021
Gynaecological cancer patients in Europe appeal for more transparency and continuation of high standard oncologic care even in times of crisis like the COVID‐19 pandemic. Abstract Background The impact of the COVID‐19 pandemic on European gynaecological cancer patients under active treatment or follow‐up has not been documented.
Murat Gultekin, Sertac Ak, Ali Ayhan, Aleksandra Strojna, Andrei Pletnev, Anna Fagotti, Anna Myriam Perrone, B. Emre Erzeneoglu, B. Esat Temiz, Birthe Lemley, Burcu Soyak, Cathy Hughes, David Cibula, Dimitrios Haidopoulos, Donal Brennan, Edoardo Cola, Elzbieta van der Steen‐Banasik, Esra Urkmez, Huseyin Akilli, Ignacio Zapardiel, Icó Tóth, Jalid Sehouli, Kamil Zalewski, Kiarash Bahremand, Luis Chiva, Mansoor Raza Mirza, Maria Papageorgiou, Novak Zoltan, Petra Adámková, Philippe Morice, Sonia Garrido‐Mallach, Utku Akgor, Vasilis Theodoulidis, Zafer Arik, Karina D. Steffensen, Christina Fotopoulou   +35 more
wiley   +1 more source

Ultrasound image analysis using deep neural networks for discriminating between benign and malignant ovarian tumors: comparison with expert subjective assessment

Ultrasound in Obstetrics &Gynecology, Volume 57, Issue 1, Page 155-163, January 2021., 2021
Abstract Objectives To develop and test the performance of computerized ultrasound image analysis using deep neural networks (DNNs) in discriminating between benign and malignant ovarian tumors and to compare its diagnostic accuracy with that of subjective assessment (SA) by an ultrasound expert.
F. Christiansen, E. L. Epstein, E. Smedberg, M. Åkerlund, K. Smith, E. Epstein   +5 more
wiley   +1 more source